Source-grounded facts extracted from Penumbra Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Penumbra Inc shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers at the 2026-06-18 meeting.
“The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 24,113,038 762,612 34,741 4,350,292”
Penumbra Inc shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.
“The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Penumbra for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 29,208,244 42,529 9,910 N/A”
Penumbra Inc shareholders approved Election of Class II Directors at the 2026-06-18 meeting.
“1) Election of Class II Directors . The following nominees were elected to serve as Class II directors until the Company’s 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified, or, if sooner, until the director’s death, resignation or removal, based on the following results of voting: Nominee Votes For Votes Withheld Broker Non-Votes Arani Bose, M.D. 21,137,932 3,772,459 4,350,292 Bridget O'Rourke 23,790,926 1,119,465 4,350,292 Surbhi Sarna 24,232,264 678,127 4,350,292”
Penumbra Inc shareholders approved Adjourn or postpone the Special Meeting to solicit additional proxies if necessary at the 2026-05-06 meeting.
“3) Adjournment Proposal . A proposal to adjourn or postpone the Special Meeting, if necessary or appropriate, to solicit additional proxies if, immediately prior to such adjournment or postponement, there were not sufficient votes to approve the Merger Proposal or to ensure that any supplement or amendment to the Proxy Statement was timely provided to the Company's stockholders, received the following votes; however, because the Merger Proposal was approved, the Adjournment Proposal was not necessary. Votes For Votes Against Abstentions Broker Non-Votes 27,309,440 1,295,803 60,690 N/A”
Penumbra Inc shareholders approved Approve, on a non-binding advisory basis, the compensation of named executive officers in connection with the Merger at the 2026-05-06 meeting.
“2) Advisory Compensation Proposal . A proposal to approve, on a non-binding, advisory basis, the compensation that the Company’s named executive officers will or may be eligible to receive in connection with the Merger, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 27,811,605 765,399 88,929 N/A”
Penumbra Inc shareholders approved Adopt the Agreement and Plan of Merger with Boston Scientific Corporation at the 2026-05-06 meeting.
“1) Merger Proposal . A proposal to adopt the Agreement and Plan of Merger (the “Merger Agreement”), dated January 14, 2026, by and among the Company, Boston Scientific Corporation, a Delaware corporation (“Parent”), and Pinehurst Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 28,564,786 85,334 15,813 N/A”
Penumbra Inc reported first quarter ended March 31, 2026 results: revenue $374.8 million, net income $32.6 million.
“Penumbra, Inc. Reports First Quarter 2026 Financial Results ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. • Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025. • Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. • Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. • Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. • Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pendin”
Penumbra Inc entered into Agreement and Plan of Merger with Boston Scientific Corporation (effective 2026-01-14).
“On January 14, 2026, Penumbra, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) among the Company, Boston Scientific Corporation, a Delaware corporation (“Parent”), and Pinehurst Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent.”
Penumbra Inc: Third Amended and Restated Bylaws adopted to phase in declassification of the Board and to eliminate supermajority voting requirements (effective 2025-05-28).
“on May 28, 2025, following stockholder approval of the Amended and Restated Charter, as described in Item 5.07 below, an amendment and restatement of the Company’s Second Amended and Restated Bylaws became effective (the “Third Amended and Restated Bylaws”).”
Penumbra Inc: Amended and Restated Certificate of Incorporation filed to phase in declassification of the Board of Directors and to replace supermajority voting requirements with a majority voting standard (effective 2025-05-28).
“On May 28, 2025, Penumbra, Inc. (“Penumbra” or the “Company”) filed an Amended and Restated Certificate of Incorporation (the “Amended and Restated Charter”) with the Secretary of State of the State of Delaware, which became effective upon such filing.”
Don Kassing retired as Director at Penumbra Inc.
“On February 14, 2025, Don Kassing, a member of the Board of Directors (the “Board”) of Penumbra, Inc. (the “Company”), notified the Company that he will retire from the Board effective April 1, 2025.”
Penumbra Inc reported the first fiscal quarter ended March 31, 2024 results: revenue $278.7 million. Guidance reaffirmed.
“Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. • Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency 1 , compared to the first quarter of 2023. • U.S. thrombectomy revenue of $150.3 million in the”
Penumbra Inc reported the fourth quarter and full year ended December 31, 2023 results: revenue $284.7 million, net income $54.2 million. Guidance reaffirmed.
“company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: • Revenue of $284.7 million for the fourth quarter of 2023, an increase of 28.7% or 27.9% in constant currency 1 compared to the fourth quarter of 2022. Revenue of $1,058.5 million for the full year 2023,”
Penumbra Inc reported the third quarter ended September 30, 2023 results: revenue $270.9 million, net income $9.2 million.
“Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2023. • Revenue of $270.9 million in the third quarter of 2023, an increase of 26.8% or 25.9% in constant currency 1 , compared to the third quarter of 2022. • Revenue of $179.1 million from sales of our”
Penumbra Inc reported full year 2023 results: revenue $1.05 billion to $1.07 billion. Guidance raised.
“The Company is increasing its guidance for 2023 total revenue to be in the range of $1.05 billion to $1.07 billion”
Penumbra Inc reported second quarter ended June 30, 2023 results: revenue $261.5 million.
“Revenue of $261.5 million in the second quarter of 2023, an increase of 25.5% as reported and in constant currency 1 compared to the second quarter of 2022.”
Penumbra Inc shareholders approved Approval, on an Advisory Basis, of the Frequency of Future Advisory Votes on the Company’s Named Executive Officer Compensation at the 2023-05-31 meeting.
“The annual frequency of future advisory votes on the compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following results of voting: One Year Two Years Three Years Abstentions Broker Non-Votes 30,831,408 16,852 63,352 9,329 4,301,558”
Penumbra Inc shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2023-05-31 meeting.
“The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 26,815,488 4,084,213 21,240 4,301,558”
Penumbra Inc shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-05-31 meeting.
“The selection of Deloitte & Touche LLP as the independent registered public accounting firm for Penumbra for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 35,135,454 79,089 7,956 N/A”
Penumbra Inc shareholders approved Election of Class II Directors at the 2023-05-31 meeting.
“The following nominees were elected to serve as Class II directors until the Company’s 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified, or, if sooner, until the director’s death, resignation or removal, based on the following results of voting: Nominee Votes For Votes Withheld Broker Non-Votes Arani Bose, M.D. 29,803,749 1,117,192 4,301,558 Bridget O'Rourke 25,870,311 5,050,630 4,301,558 Surbhi Sarna 26,148,112 4,772,829 4,301,558”
Penumbra Inc reported the first quarter ended March 31, 2023 results: revenue $241.4 million. Guidance raised.
“Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2023. • Revenue of $241.4 million in the first quarter of 2023, an increase of 18.4%, or 19.7% in constant currency 1 , compared to the first quarter of 2022. First Quarter 2023 Financial Results Total revenue”
Penumbra Inc reported the full year ended December 31, 2022 results: revenue $847.1 million.
“Revenue of $847.1 million for the full year 2022, an increase of 13.3% compared to revenue of $747.6 million for the full year 2021, or an increase of 15.5% in constant currency 1 .”
Penumbra Inc reported the fourth quarter ended December 31, 2022 results: revenue $221.2 million.
“Revenue of $221.2 million for the fourth quarter of 2022, an increase of 8.4% compared to revenue of $204.0 million for the fourth quarter of 2021, or an increase of 10.5% in constant currency (a non-GAAP measure) 1 .”
Penumbra Inc updated its 2022 guidance (lowered).
“The Company now expects 2022 total revenue to be in the range of $840 million to $845 million, which reflects growth of 12-13% on a reported basis and 15-16% in constant currency compared to 2021.”
Penumbra Inc reported the third quarter ended September 30, 2022 results: revenue $213.7 million. Guidance lowered.
“Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2022. • Revenue of $213.7 million in the third quarter of 2022, an increase of 12.4%, or 15.1% in constant currency 1 , compared to the third quarter of 2021. Third Quarter 2022 Financial Results Total revenue”
Lynn Rothman departed as Executive Vice President and Chief Business Officer at Penumbra Inc.
“Lynn Rothman, the Executive Vice President and Chief Business Officer of Penumbra, Inc. (the “Company”), notified the Company of her departure, effective May 2, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.